Get the Stockscreener App
197.48
1.38%
2.69
After Hours:
198.00
0.52
+0.26%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $197.48, with a volume of 3.57M.
It is up +1.38% in the last 24 hours and up +0.60% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$194.79
Open:
$194.85
24h Volume:
3.57M
Relative Volume:
0.75
Market Cap:
$348.80B
Revenue:
$55.00B
Net Income/Loss:
$5.34B
P/E Ratio:
54.10
EPS:
3.65
Net Cash Flow:
$17.78B
1W Performance:
+1.88%
1M Performance:
+0.60%
6M Performance:
+8.45%
1Y Performance:
+32.48%
1-Day Range:
$194.37
$197.62
1-Week Range:
$189.62
$197.62
52-Week Range:
$135.85
$199.95
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie (NYSE:ABBV) Trading Up 0.4% - MarketBeat
AbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 Years - Yahoo Finance
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V - Nasdaq
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V - Zacks Investment Research
Questex’s Digital Pharma East Brought Pharma Marketing Professionals Together to Ignite Innovative Discussions and Marketing Strategies to Shape the Future of the Industry - GlobeNewswire Inc.
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - Yahoo Finance
AbbVie seeks FDA approval for non-small cell lung cancer treatment - Pharmaceutical Business Review
15 Best Dividend Stocks for Lifelong Passive Income - The Motley Fool
AbbVie Inc. (NYSE:ABBV) is Regal Investment Advisors LLC's 10th Largest Position - MarketBeat
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials - MSN
AbbVie: Dividend Discount Model Suggests Large Valuation Risks (NYSE:ABBV) - Seeking Alpha
Annandale Capital LLC Has $4.99 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Alethea Capital Management LLC Makes New $488,000 Investment in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie (NYSE:ABBV) Stock Price Up 1.5% - MarketBeat
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal - Yahoo Finance
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer - Marketscreener.com
AbbVie submits BLA for antibody-drug conjugate Teliso-V for NSCLC - Seeking Alpha
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer - StockTitan
Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar
AbbVie’s tavapadon meets primary endpoint in Phase 3 Parkinson’s disease trial - World Pharmaceutical Frontiers
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Legal & General Group Plc - MarketBeat
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial - Clinical Trials Arena
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial - Yahoo Finance
How AbbVie is working to push boundaries in mental health research - AbbVie
AbbVie’s Tavapadon Demonstrates Efficacy In Parkinson’s Monotherapy Study - Scrip
AbbVie Inc. stock rises Thursday, still underperforms market - MarketWatch
AbbVie’s Parkinson’s Disease drug meets main goal in late-stage trial - WTVB
AbbVie (NYSE:ABBV) Trading 0.1% Higher - MarketBeat
AbbVie’s tavapadon offers encouragement in Parkinson’s - The Pharma Letter
OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées - GlobeNewswire Inc.
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease - Yahoo Finance
AbbVie Parkinson’s drug helps improve symptoms in late-stage study - STAT
AbbVie posts trial win for Parkinson's drug (NYSE:ABBV) - Seeking Alpha
AbbVie's Parkinson's disease drug meets main goal in late-stage trial - Marketscreener.com
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study - MarketWatch
AbbVie's Parkinson's disease drug meets main goal in late-stage trial - Yahoo Finance
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease - PR Newswire
Bristol Myers Squibb Vs. AbbVie Stock - Forbes
Daymark Wealth Partners LLC Acquires 33,981 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials - Clinical Trials Arena
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials - Yahoo Finance
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (NYSE:ABBV) Shares Down 0.7% - MarketBeat
Three ways AI is changing drug discovery at AbbVie - AbbVie
Abbvie Worker Advances Suit Over Family Medical History Queries - Bloomberg Law
Axa S.A. Sells 63,943 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Anti-retroviral Drugs Market to hit USD 42.5 billion by 2032, says Global Market Insights Inc. - GlobeNewswire Inc.
Abbott Laboratories (NYSE:ABT) Trading Down 0.5% - Defense World
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):